Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Moderna's COVID-19 Vaccine Update Boosts Antibodies 16-Fold, Data Shows

Barishal,,Bnagladesh.,07-08-2021:,Some,Doses,Of,Moderna,Covid19,Vaccines,Are

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE (COVID-19 Vaccine, mRNA), which targets the LP.8.1 variant of SARS-CoV-2.

The data from an ongoing Phase 4 clinical trial evaluating the safety, tolerability, and immunogenicity of the 2025-2026 formula of mNEXSPIKE showed, on average, greater than a 16-fold increase in neutralizing antibodies against the LP.8.1 variant in individuals 12 through 64 years of age with at least one underlying condition and all adults 65 years of age and older.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.